Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

被引：0
|
作者：
McBride, Ali
Campbell, Kim
Bikkina, Mohan
MacDonald, Karen
Abraham, Ivo
Balu, Sanjeev
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3380
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prophylaxis of chemotherapy-induced neutropenia (CIN) with filgrastim biosimilar Ratiograstim® - results from the prospective non-interventional study (NIS) "RatioNeu"
    Jungberg, P.
    Juenemann, R.
    Schroeder, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 38 - 38
  • [32] Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk calculator (MONITOR-GCSF study)
    Aapro, M.
    Ludwig, H.
    Bokemeyer, C.
    Gascon, P.
    Boccadoro, M.
    Turner, M.
    Denhaerynck, K.
    MacDonald, K.
    Abraham, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S236 - S236
  • [33] Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
    Abeer A. Al-Rabayah
    Ola Al Mashni
    Esraa Hanoun
    Weam Al Qasem
    Deema Al Momani
    Rawan Fawzi Al Froukh
    Razan Sawalha
    Suzan S. Hammoudeh
    Drugs - Real World Outcomes, 2022, 9 : 589 - 595
  • [34] Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
    Al-Rabayah, Abeer A.
    Al Mashni, Ola
    Hanoun, Esraa
    Al Qasem, Weam
    Al Momani, Deema
    Al Froukh, Rawan Fawzi
    Sawalha, Razan
    Hammoudeh, Suzan S.
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 589 - 595
  • [35] Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
    Aapro, Matti
    Bokemeyer, Carsten
    Ludwig, Heinz
    Gascon, Pere
    Boccadoro, Mario
    Denhaerynck, Kris
    Gorray, Michael
    Krendyukov, Andriy
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (02) : 86 - 95
  • [36] Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Rosencher, Nadia
    Boccadoro, M.
    Turner, Matthew
    MacDonald, Karen
    Muenzberg, Michael
    Abraham, Ivo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 (03) : 198 - 200
  • [37] Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study
    McBride, Ali
    Campbell, Kim
    Bikkina, Mohan
    MacDonald, Karen
    Abraham, Ivo
    Balu, Sanjeev
    CANCER RESEARCH, 2018, 78 (04)
  • [38] Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2107 - 2113
  • [39] Treatment patterns and outcomes in patients with non-small cell lung cancer (NSCLC) receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia: Results from the MONITOR-GCSF study
    Aapro, M.
    Krendyukov, A.
    Hobel, N.
    Gascon, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR
    Fietz, Thomas
    Lueck, Andreas
    Schulz, Holger
    Harde, Johanna
    Losem, Christoph
    Grebhardt, Sina
    Wolff, Thomas
    Potthoff, Karin
    Mueller, Udo
    Zaiss, Matthias
    Kurbacher, Christian Martin
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1127 - 1138
12345